- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03575819
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study will test the safety and efficacy of FOR46 given every 21 days to patients with metastatic castration-resistant prostate cancer.
The name of the study drug involved in this study is: FOR46 for Injection (FOR46)
Study Overview
Detailed Description
This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46 in patients with metastatic castration-resistant prostate cancer. This study will be conducted in two parts:
Dose escalation:
This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once this dose is shown to be safe, a second patient will be enrolled at the next higher dose. Patients will continue to be enrolled into either single or multiple patient groups receiving increasing doses until the MTD is reached.
Dose expansion:
This part of the study will further evaluate the safety, tolerability and antitumor activity of FOR46 at a dose shown to be safe in the dose escalation part of the study. Patients will be enrolled into 1 of 2 groups, based on histology.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Institute of Urologic Oncology
-
San Francisco, California, United States, 94143
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Oregon
-
Portland, Oregon, United States, 06903
- OHSU Knight Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male ≥ 18 years of age
- Has histologically confirmed prostate cancer that is metastatic and has progressed as defined by PCWG3 criteria during or after treatment with at least 1 ASI (eg, abiraterone, enzalutamide, apalutamide), or another second-generation anti-androgen or cytochrome P450 (CYP)17A1 inhibitor, with the most recent ASI administered in the castration-resistant setting
- Has serum testosterone levels < 50 ng/dL during screening. Patients without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy
- ECOG performance status of 0 or 1
- Adequate hematologic, renal and hepatic function
- Males with female partners of childbearing potential must agree to use 2 effective methods of contraception
- Patients must provide signed informed consent
- Patients enrolled into the dose expansion phase must have prostate carcinoma without histologic evidence of small-cell/neuroendocrine carcinoma features on prior biopsy or must have unequivocal histologic evidence of small-cell/neuroendocrine prostate carcinoma (pure or mixed). Patients with treatment-emergent small-cell neuroendocrine cancer (pure or mixed) may have received no more than on prior chemotherapy regimen for mCRPC
- Patients enrolled into the dose expansion phase must be willing to undergo a metastatic tumor biopsy or has tissue available from a prior post-castration resistant tumor biopsy
Exclusion Criteria:
- Persistent clinically significant toxicities from previous anticancer therapy
- Has NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology or has a genetic disorder that is associated with peripheral neuropathy even without current neuropathic manifestations
- Prior treatment with cytotoxic chemotherapy for mCRPC (chemotherapy in the hormone-sensitive setting is allowed if > 6 months before study entry)
- Has received external-beam radiation or systemic anticancer therapy within 14 days before first dose of FOR46
- Has received treatment with an investigational drug within 28 days before first dose of FOR46
- Has had a major surgical procedure within 28 days before administration of FOR46 dose
- Clinically significant cardiovascular disease
- Uncontrolled, clinically significant pulmonary disease
- Has a history of brain or leptomeningeal metastases.
- Uncontrolled intercurrent illness
- Has a known positive status for HIV or either active/chronic hepatitis B/C
- Requires medications that are strong inhibitors or strong inducers of CYP3A4
- [Dose escalation only] Has a history of episodic atrial fibrillation or flutter (patients with chronic atrial fibrillation are not excluded)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOR46 (Dose Escalation)
Eligible patients will receive FOR46 administered as an IV infusion every 21 days.
Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
|
FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
|
Experimental: FOR46 (Dose Expansion)
Eligible patients will receive FOR46 administered as an IV infusion every 21 days.
Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
|
FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of dose-limiting toxicities
Time Frame: Through 1 month following last dose
|
The severity and incidence of dose-limiting toxicities related to escalating dose levels of FOR46
|
Through 1 month following last dose
|
Occurrence of toxicity
Time Frame: Through 1 month following last dose
|
Type, incidence, severity, seriousness, and relatedness of adverse events.
|
Through 1 month following last dose
|
Disease response/composite response
Time Frame: 12 months
|
Decline in serum prostate-specific antigen greater than 50% from baseline, confirmed by repeat measurement and objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize FOR46 plasma concentration
Time Frame: Through 1 month following last dose
|
FOR46 maximum plasma concentration
|
Through 1 month following last dose
|
Characterize the FOR46 area under the curve
Time Frame: Through 1 month following last dose
|
FOR46 area under the plasma concentration-time curve
|
Through 1 month following last dose
|
Characterize FOR46 elimination
Time Frame: Through 1 month following last dose
|
FOR46 elimination half-life
|
Through 1 month following last dose
|
Antidrug Antibodies
Time Frame: Through 1 month following last dose
|
Change from baseline in serum levels of antidrug antibodies
|
Through 1 month following last dose
|
Median radiographic progression-free survival
Time Frame: 12 months
|
Assessed by Prostate Cancer Clinical Trials Working Group 3 criteria
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Endpoint: Tumor expression of CD46
Time Frame: Through 1 month following last dose
|
Association between level of tumor expression of CD46 by immunohistochemistry (IHC) analysis with clinical outcomes
|
Through 1 month following last dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Andrew Dorr, MD, Fortis Therapeutics, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FOR46-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
WntResearch ABCompletedMetastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Colon CancerDenmark, United Kingdom
Clinical Trials on FOR46
-
Fortis Therapeutics, Inc.CompletedMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed RemissionUnited States
-
Rahul AggarwalFortis Therapeutics, Inc.RecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States